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Abstract
Reducing the global diseases burden requires effective diagnosis and treatment. In the developing world,
accurate diagnosis can be the most expensive and time-consuming aspect of health care. Healthcare cost can,
however, be reduced by use of affordable rapid diagnostic tests (RDTs). In the developed world, low-cost
RDTs are being developed in many research laboratories; however, they are not being equally adopted in the
developing countries. This disconnect points to a gap in the design philosophy, where parameterization of
design variables ignores the most critical component of the system, the point-of-use stakeholders (e.g.,
doctors, nurses and patients). Herein, we demonstrated that a general focus on reducing cost (i.e., “low-cost”),
rather than efficiency and reliability is misguided by the assumption that poverty reduces the value individuals
place on their well-being. A case study of clinicians in Kenya showed that “zero-cost” is a low-weight
parameter for point-of-use stakeholders, while reliability and standardization are crucial. We therefore argue
that a user-driven, value-addition systems-engineering approach is needed for the design of RDTs to enhance
adoption and translation into the field.
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Abstract: Reducing the global diseases burden requires effective diagnosis and treatment. In the
developing world, accurate diagnosis can be the most expensive and time-consuming aspect of
health care. Healthcare cost can, however, be reduced by use of affordable rapid diagnostic tests
(RDTs). In the developed world, low-cost RDTs are being developed in many research laboratories;
however, they are not being equally adopted in the developing countries. This disconnect points
to a gap in the design philosophy, where parameterization of design variables ignores the most
critical component of the system, the point-of-use stakeholders (e.g., doctors, nurses and patients).
Herein, we demonstrated that a general focus on reducing cost (i.e., “low-cost”), rather than efficiency
and reliability is misguided by the assumption that poverty reduces the value individuals place
on their well-being. A case study of clinicians in Kenya showed that “zero-cost” is a low-weight
parameter for point-of-use stakeholders, while reliability and standardization are crucial. We therefore
argue that a user-driven, value-addition systems-engineering approach is needed for the design of
RDTs to enhance adoption and translation into the field.
Keywords: low cost; diagnostics; technology adoption; value-added design; health care; rapid
diagnostics
1. Background
Affordable and accessible health care is a major challenge to national development. For example,
in Kenya, 51% of health care is paid for out of pocket, and 46% of the population lives on US $1.00
or less per day [1,2]. This combination of low income and high out-of-pocket costs for healthcare makes
it imperative to keep overall health-care costs low. Health care consists of three interlinked areas:
disease prevention, diagnosis and treatment. Disease prevention and treatment have received much
attention recently with widespread immunization and treatment programs organized by international
Micromachines 2017, 8, 317; doi:10.3390/mi8110317 www.mdpi.com/journal/micromachines
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organizations such as the World Health Organization (WHO), but advances in affordable disease
diagnostics have lagged behind leading to an over-reliance on clinical symptoms [3]. The reliance on
symptoms is partly attributed to the fact that many laboratories in developing countries are not well
equipped [4] and lack well-maintained equipment and/or skilled laboratory personnel.
The dire need for better health care among the world’s less-fortunate has garnered the attention
of scientists and engineers in the developed world [5], who are developing rapid diagnostic tests
(RDTs) with a current rise in paper-based devices, with long shelf lives that do not rely on advanced
equipment or trained personnel and can supplement clinical symptom diagnosis based on different
materials and detection modalities [5–14]. Over the last four decades, RDTs for common diseases such
as HIV [15] and malaria [16] have been developed, and some have been adopted in the field. A number
of reports on recent developments in RDTs have appeared in the literature [17–25] but are beyond the
scope of the current report. Despite the rapid increase in the number of RDTs studies, Whitesides and
co-workers observed a huge discrepancy in the number of published papers on laboratory studies
versus field testing and adoption [5]. Miller et al. also noted that, of the RDTs that have recently been
developed in research laboratories, few have been adopted by the target end users [26].
A number of studies have shown that although RDTs can significantly reduce disease prevalence
and improve the well-being of populations in the developing world [27–29], they have not been widely
adopted. The use and impact of RDTs across the world, for example in Nigeria [30], Uganda [31],
France [32], Tanzania [33], and Ghana [34], is complicated by user perceptions. All studies reported
both positive (e.g., better clinical diagnosis) and negative (e.g., increased workload, reliability, and cost)
perceptions of RDTs, complicating technology adoption.
Technology adoption, from development to use, is a challenge, even when the technology
has definite benefits for potential users [35]. The technology acceptance model (TAM) argues that
behavioral intentions to use a new technology depends on its perceived usefulness and perceived
ease of use [36]. Low-cost RDTs must, therefore, affirm to users their value before gaining their
trust [37,38]. Trust, however, is two-tiered: (i) Confidence in the goodwill of others not to cause harm
to a vulnerable person. For most developing countries, this trust is complicated by colonial history
and effect of prior experiences with international development programs. (ii) Trust in the technology
to better the quality of life of the user—which RDTs must gain if they are to translate from a research
curiosity to use [39–43]. Trust in a technology can be eroded by inaccuracies and repeated failures,
making it important for developers to learn what challenges users encounter and how they relate to the
adoption of the technology. To ensure continued trust in a technology, iterative development is often
desired where the user informs newer versions of the technology-design. This information, from all
stakeholders, is combined into a technology development system, which in turns informs which
enabling technologies are best suited for the particular market or challenge. It is therefore imperative
that constant communication between technology developers and end-use occur if the problem is to
be adequately addressed. The developed technologies, however, are based on fundamental scientific,
business, socio-cultural, and geo-political knowledge. Increasing the quality of this fundamental
knowledge will make more technologies available (increase competition and choice), which can lead to
an increase in adoption by the end-user (key stakeholders) as long as their values are met (Figure 1A).
The design challenge can, therefore, be broken down into three tiered structures: the fundamental
knowledge base, integration of this information into enabling technologies, and finally the field
(point-of-use healthcare and business environment), i.e., the users’ system (Figure 1A). Complexity
in each of the micro-systems challenges the technology developers, and, we believe, is the basis of
poor translation of many otherwise well designed enabling technologies. Besides, each tier has its own
challenges, with the fundamental knowledge being complicated by the diverse nature of data (from
physical and social sciences), enabling technologies being limited by state-of-the-art while diversity in
culture and political landscape makes comprehension of health care systems challenging. For example,
while the west relies on individual health insurance, in Kenya, for example, the community acts as
the safety net through so called “harambees”—public fundraising events or the social responsibility of
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relatives to each other. It is therefore difficult to define the buying power of a healthcare market without
understanding the potential (value) of life in these communities and associated micro-communities.
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stakeholder but with the end-user definition carrying a higher weight. Attributes are derived from 
the stakeholders and the drivers of the design and fabrication (abbreviated “fab”) and cost. The 
existence of feedback loops during the design process allows for efficiency and appropriateness in 
the design, production and adoption of the product. 
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models are particularly useful in obtaining the requirements in a system, communicating goals to 
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existing problems that stakeholders will adopt. For RDTs to be adopted, their design cannot solely 
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Figure 1. An expanded view of the challenges and approaches to effective design of affordable
RDTs. (A) Three tier schematic diagram of the different critical levels in the design process with
their associated barriers. Tier 1 captures all fundamental knowledge associated with diagnostics and
healthcare, while Tier 2 is the enabling technologies that are then translated to Tier 3 here capturing
the local health care system and associated socio-cultural structures. All three tiers make the overall
system. (B) Systems engineering approach to design of low-cost RDTs with the capture capturing the
underlying V- odel but specifically focusing on value addition here “value” is dictated by each
stakeholder but with the end-user definition carrying a higher weight. Attributes are derived from the
stakeholders and the drivers of the design and fabrication (abbreviated “fab”) and cost. The existence
of feedback loops during the design process allows for efficiency and appropriateness in the design,
production and adoption of the roduct.
The challenge of understanding complicated macro-systems and design environments is, however,
not new. System engineering provides a rigorous approach to the conception, design, manufacturing
and retiring (end-of-life management) of technology in otherwise complex systems. This approach is
made possible by use of various frameworks within systems engineering such as the V-model (insert
Figure 1B), the waterfall model and the spiral model needed to generate and keep track of goals and
progress throughout the lifetime of an engineering endeavor [44]. The models are particularly useful
in obtaining the requirements in a system, communicating goals to designers and to measure progress.
These requirements also represent the stakeholders’ desires. These models have also demonstrated
the importance of end-user decision-making early in the design process especially for a complex
system [45]. Value-Driven Design (VDD) provides a platform for capturing these desires and to
communicate them throughout the development process (Figure 1B) [46]. At the pinnacle of this
model is integration of “value” into the design process. Bloebaum and co-workers [45,46] have
explained this model elsewhere, a task beyond the scope of this report. The VVD model ensures that
the outputs—systems or products—are elegant solutions to existing problems that stakeholders will
adopt. For RDTs to be adopted, their design cannot solely be based on the designers’ assumptions,
but requires input from the stakeholders about all barriers and challenges to the effective adoption
and trust in the technology. End user input is therefore critical. To ascertain the validity of this
inference, we explored the perception of clinicians in Kenya with the goal of understanding some of
the challenges and blind-spots in the design process.
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2. Case-Study: Barriers to Adoption of Low-Cost RDTs in Kenya
Based on the VDD model, and a desire to design for translation/adoption, we sought to
understand the most critical variables for an effective adoption of RDTs in Kenya. In Kenya, medical tests
are generally ordered by clinicians (i.e., physician assistants—so-called clinical officers—and medical
doctors). Because the clinicians decide which tests are done and patient generally trust a clinician’s
judgment, we hypothesized that the opinion of the clinicians is representative of the point-of-care
stakeholders (end-users) with regards to RDTs. This study had two goals: (1) to determine why
RDTs are not adopted en mass by target users in the developing world; and (2) how to improve
the design to promote adoption. We hypothesized that limited involvement of developing-world
users (e.g., clinicians, academicians, policy makers, and entrepreneurs) in the design and validation
of these RDTs in the developed nation’s laboratories is a potential reason for their poor translation
from the western laboratories to the point of care. Although self-reporting is less accurate than direct
observation, this study was designed to provide baseline results and elucidate the general factors
behind the inertia in adopting RDTs. We investigated the self-reported knowledge and opinions of
Kenyan clinicians about RDTs across different hospital tiers and across three different economic zones:
urban, suburban, and rural–urban. This sample is representative for clinicians across most of the
country. The general awareness and familiarity with RDTs among clinicians is high: There were a total
of 123 valid responses from the clinicians, with 58 responses each from high- and mid-tier hospitals and
only seven from the lowest-tier hospitals; the latter is because of the structure of the Kenyan health-care
system. A lack of clinical officers and medical doctors in rural low-tier hospitals made it impossible to
obtain a statistically significant sample from this tier. The targeted hospitals in the rural–urban zone,
however, offered insight into the use of RDTs in rural settings because these hospitals are the local
referral centers for rural clinics.
3. Results and Discussion
Upon acceptance of an invitation to participate in this study, feedback was obtained in a maximum
of two days. Qualitative analysis was done through thematic coding of the open-ended responses,
classifying and summarizing the information, and presenting it in descriptive form. The validity and
reliability of the perceptions scale were established using the Cronbach’s alpha (0.81–0.93 for usability
and reliability, and 0.23 for adoptability) [43]. All experimental and data analysis details are given in
the supporting information.
We decided not to consider responses from the lowest tier for statistical analysis due to the small
sample size; however, comparative qualitative data were considered.
All respondents indicated familiarity with RDTs, and a majority (86%) affirmed that RDTs
are fundamental for disease diagnosis in Kenya with speed of the tests being their main reason
(Figure 2). Clinicians affirmed that RDTs are essential in improving diagnosis and healthcare
delivery in the country (Figure 2). The respondents also indicated that RDTs can replace advanced
techniques such as microscopy where appropriate (Figure 2). The obvious advantages of RDTs in
the Kenyan healthcare systems were also evident from the acknowledgement that these devices
have the potential to make healthcare more affordable in Kenya (Figure 2). The surveyed Kenyan
clinicians are conversant with various RDTs (Figure 3A), therefore knowledge of the technology
was not a primary reason for the slow translation. Familiarity not only with the specific tests but
also with the general overarching technologies can increase RDT adoption by decreasing natural
resistance to new experiences. To determine familiarity, the clinicians were asked which specific
RDT technologies they had used. A majority indicated solid phase/dipstick and agglutination tests
(73% each), and a smaller proportion (<15%) identified lateral flow or flow-through devices (Figure 3A).
Only a very small fraction had no knowledge of any of the above tests (2%). These data confirm that
perceived usefulness, knowledge, and familiarity, are not the critical barriers in adoption of affordable
RDTs. For clarity, a summary of the qualitative data (Figure 2) in the form of pie charts is also provided
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in the Supplementary Materials, alongside the level of training the clinicians had attained (Figures S1
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Affirmative responses are given on the left, while negations are given on the right. The unmarked
regions represent number of neutral responses.
Knowledge about diseases that can be tested for with RDTs is also not a critical barrier (Figure 3B).
Most clinicians (95%) named at least one disease (with 71% naming 2, and 24% naming ≥3),
while a minority (5%) could not name any disease that used RDTs for diagnosis. When comparing
this knowledge to whether they had used these tests themselves, it was surprising that only about
10% of the respondents that knew of ≥3 diseases that can be diagnosed with RDTs had applied
them in their practice. Although a majority (81%) had diagnosed one or two diseases with an RDT,
11% had never used one. Malaria and HIV, as expected [46,47], were the most common applications for
RDTs, although syphilis, pregnancy, typhoid, and diabetes were mentioned (Figure 3B). Doctors from
socio-economically well-off hospitals demonstrated overall better knowledge and higher usage of
RDTs in HIV testing compared to their rural counterparts. For malaria, however, there was a large
discrepancy between RDT knowledge (57%) and use (36%), irrespective of the tier of the hospital.
There are multiple possible reasons for this discrepancy: (1) RDTs may not be perceived as being
useful for malaria diagnosis–since symptoms manifest very strongly and the spike in disease cases
is predictable based on the season; (2) RDTs might not be available to clinicians; (3) RDTs may not
complement other diagnostic approaches; or (4) the clinicians may have great success with other more
rapid diagnostic approaches, such as identifying symptoms. For all other conditions, knowledge about
the existence of RDTs for diagnosis was 1.25 to 3.25 times higher than their clinical use.
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consistent with the finding that only 35% of the clinicians withheld medication when a patient’s test 
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Figure 3. Feedback on knowledge, use and challenges in adoption of RDTs: (A) knowledge about
specific technologies for RDTs; (B) percentage of clinicians that had heard about (black) or used (white)
RDT for a specific disease—multiple answers possible; and (C) barriers encountered and perceived
changes needed in RDTs. The large difference in “reliability” comes from doctors indicating both
reliability and standardization, which will make results more reliable, as a change to unreliable RDTs.
4. What Are the Main Barriers to Adopting R Ts?
Inasmuch as dopting a technology is relat t tr ting it, encountering barriers while using
RDTs is detrimental to their adoption- erodes tr technology. Clin cians indicated hat their
patien s were sati fied with e r sults derived from RDTs (97%), and would recommend RDTs for use
in the future (96%). When the clinicians were asked if they thought that RDTs gave reliably accurate
results, however, only half (50%) were affirmative, whereas al ost half (46%) were unsure about these
tests and a small proportion (4%) thought of them as inaccurate. This result is consistent with the
finding that only 35% of the clinicians withheld medication when a patient’s test result was negative
and that only 20% relied solely on the tests—most clinicians who gave a written reason for their answer
mentioned the need to complement RDT results with the observation of clinical symptoms.
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More than half of the respondents (54%) reported encountering barriers to using RDTs, and the
likelihood of encountering a barrier increased as the hospital tier decreased (45% in the highest-tier
hospitals and 53% in mid-tier hospitals). Of those who had encountered barriers, half (50%) indicated
reliability (false positives and/or false negatives) as a major obstacle, which is one possible reason
these clinicians might prescribe medication to patients with negative test results (Figure 3C).
Availability of the tests or their components (46%) was the second major obstacle (Figure 3C).
Only a small group considered cost (14%) or the lack of awareness/training (12%) to be major
barriers. To add the point-of-use stakeholders to the system and inform the design of RDTs for
increased adoption, clinicians were asked to suggest changes that are needed to increase RDT use.
Nearly half (44%) suggested improving the tests themselves, with 22% suggesting improving reliability,
and 20% suggesting standardization—the latter was not listed as a possible barrier in the questionnaire
but they wrote it in. Increased availability was another needed change (22%), followed by awareness
and training (20%); the smallest (12%) consideration was given to the tests’ costs (Figure 3C). Despite the
perceived challenges and needed improvements, a majority (85%) of the clinicians sampled agreed
that RDTs can make health care more affordable in Kenya (Figure 2).
With the discrepancy between the focus on low-cost or even “zero-cost” in the developed world
laboratories and the low perception of cost as a needed change in the developing world, there is a need
to rethink the design strategies for RDTs. A race to zero-cost diagnostics seems unnecessary, especially
when it is combined with a decline in the quality of RDTs. Besides, socio-cultural history (primarily
colonialism and a perceived social engineering [48,49]) amongst Africans, imposes an inherent
mistrust of zero-cost products, especially when such products are from the developed world.
Increasing community participation in an individual’s care (through public fund-raising i.e., harambee),
offers an unprecedented high-level of “insurance” that allows an individual to go for quality care
beyond what they can afford based on their daily earnings. It is therefore possible that a focus
on an individual’s daily income as a design variable is an invalid consideration, but rather the
perceived “threat” of a disease should inform the RDT designer. Surprisingly, the doctors confirmed
this observation by indicating that a cost of ~$1 (mean suggested costs of $0.5 ± $0.3 (mid-tier) to
$0.7 ± $0.3 (high tier)) was appropriate (Figure 4). The full range of suggested values were extremely
spread out with some outlier suggestions ranging from free ($0, mostly mid-tier) to $25 (mostly
high-end hospital clinicians) as captured by the data spread (Figure 4). It is therefore clear that
advocacy for zero-cost diagnostic tools [6–9] will not likely increase adoption, at least in the Kenyan
case, while increasing reliability and standardization can. This data also indicate that device complexity
can be slightly increased to ensure reliability, standardization and ease of use.
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5. Conclusions: What We Learned
The observed unreliability of RDTs is a major drawback to their use and can lead to low-quality
services and loss of trust in these tools. This study identified self-reported mistrust of RDTs in Kenya
due to consistent unreliability, and hence low perceived usefulness. To regain the clinicians’ trust,
RDT development must focus on the tests’ efficiency, accuracy, and reliability, and more studies
are needed to determine the importance of each of these factors during development. Establishing
analytical control (standardization) while also increasing availability appeared to be more desirable to
the clinicians than a focus on very low cost devices, especially when the low prices are accompanied
with the loss of accuracy, reliability, and availability. The Kenyan clinicians’ responses suggest that,
although the populations may not be wealthy, they highly value their health, to the extent that they are
willing to spend more than a day’s wage on diagnosis. This conclusion, however, is from the doctor’s
perspective and should be corroborated by the patients.
We further considered the engineering aspects of RDTs, particularly in the form of the device
technology. The answers in our study indicated that simple technologies, such as dipstick and
agglutination tests, were better known than more complicated ones. Although developing new RDTs
with technologies that are more familiar to the intended user can lead to more rapid adoption of
these methods, the low trust in the existing tests must be considered. It is therefore critical that
those involved in RDT design (low-cost platforms such as paper-based devices) consider integrating
a team from the target market/healthcare system if adoption and translation is critical in the design.
The current norm of taking the already developed devices for “testing” in the field is bound to fail
unless the end-user is integrated as part of the device development team [47,50,51].
6. Outlook: New Design Paradigm
Instead of largely focusing on cost, RDT designers and developers need to consider all aspects
of the systems variables to produce affordable and reliable (not necessarily low-cost) diagnostic
tools in which all stakeholders dictate the desired device attributes (Figure 1B). To determine what
these aspects are, and how they are weighted by the doctors and patients, we propose adoption of
Value-Driven Design (VDD) models in a systems engineering approach with the end-user playing
an early role [45]. This approach embeds the weighted value of a technology to the patient’s life and
reflects the socio-cultural background which it is being designed for. For this approach, we need input
from all stakeholders including developers, policy makers, manufacturers, and, most importantly,
doctors and patients at the point-of-use. We need to understand how to best “provide required
resources and information for people in low- and middle-income economies in their voyage” [47]
toward good health. Only an integrated systems design approach will increase the adoption of RDTs in
developing countries, by eliminating the type of dissonance observed in the current study. Whereas we
propose a new design paradigm, significant advances have been made in the technology development
and development of fundamental knowledge in diagnosis (Figure 1A, Tier 1 and Tier 2). What is
lacking, however, is an integration of this information into a diagnostic kit that is user-inspired.
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